Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On April 12, 2021, Clay B. Siegall, Ph.D., notified Ultragenyx
Pharmaceutical Inc. (the "Company") that he will not stand for re-election as a
director of the Company upon the expiration of his current term at the Company's
2021 annual meeting of stockholders (the "2021 Annual Meeting"). Dr. Siegall
will continue to serve as a director of the Company until the 2021 Annual
Meeting. Dr. Siegall's decision to let his term expire and not to stand for
re-election at the 2021 Annual Meeting is for personal reasons and not related
to any disagreement with the Company on its operations, policies or practices.
(d) Exhibits
Exhibit No. Description
104 The cover page from the Company's Current Report on Form 8-K dated
April 12, 2021 formatted in Inline XBRL.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses